drugset / Trial / NCT02578121
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
Timeline
- Start
- 2015-12
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Ixazomib | Unknown | 4 mg | — |
| Subject | Pomalidomide | Other / unclassified | 4 mg | — |